EU And US Orphan Drug Regimes: Benefits And Limitations Of International Cooperation
Executive Summary
Daniel Kracov and Jackie Mulryne analyze the differences in data requirements for the authorization of orphan medicines in the EU and the US and the challenges they pose for global drug development.